Roth Capital Trims PT on BioBlast (ORPN) to $15; New Focus is Tough, But Necessary, Decision
Tweet Send to a Friend
Roth Capital trims its price target on Buy-rated BioBlast Pharma (Nasdaq: ORPN) from $23 down to $15 after BioBlast announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
